非布司他能够治愈痛风吗？

Febuxostat (febuxostat, feburic) was launched in Europe in 2008, in the United States in 2009, and in China since 2013. This product is a xanthine oxidase (XO) inhibitor and is suitable for the long-term treatment of hyperuricemia with gout symptoms. Can febuxostat cure gout?

It is understood that although Febus is effective in treating gout, it cannot cure gout.

Gout is a crystal-related arthropathy caused by the deposition of monosodium urate (MSU). It is directly related to hyperuricemia caused by purine metabolism disorder and/or reduced uric acid excretion. It specifically refers to acute characteristic arthritis and chronic tophi disease. Febuxostat (febuxostat, feburic) is mainly used for the long-term treatment of hyperuricemia in patients with gout and can have a certain effect, but it is not recommended for use in asymptomatic hyperuricemia. Febuxostat tablets are contraindicated in patients receiving azathioprine and mercaptopurine treatment.

Febuxostat (febuxostat, feburic) will not affect the synthesis and metabolism of other purine pyrimidines at conventional therapeutic concentrations. It can exert high activity in small doses and is relatively safe. It has accurate efficacy and good safety and tolerance for patients who are not suitable for allopurinol treatment. In November 2017, based on the final results of the CARES study, the US FDA warned in a drug safety communication that febuxostat may increase the risk of heart-related death. The CARES study showed that in patients with gout and a history of cardiovascular disease, febuxostat (febuxostat, feburic) had similar adverse event rates to allopurinol and higher cardiovascular mortality than allopurinol. Although the causal relationship between febuxostat and cardiovascular thrombotic events has not yet been determined, or the conclusions of the CARES study need to be further verified in Asian or Chinese patients, attention should be paid to monitoring the symptoms and signs of myocardial infarction and stroke when using the drug.